Cusick Sarah E, Opoka Robert O, Abrams Steven A, John Chandy C, Georgieff Michael K, Mupere Ezekiel
Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis, MN;
Departament of Paediatrics and Child Health, College of Health Sciences, Makerere University, Kampala, Uganda;
J Nutr. 2016 Sep;146(9):1769-74. doi: 10.3945/jn.116.233239. Epub 2016 Jun 29.
Iron therapy begun concurrently with antimalarial treatment may not be well absorbed because of malaria-induced inflammation. Delaying the start of iron therapy may permit better iron absorption and distribution.
We compared erythrocyte iron incorporation in children who started iron supplementation concurrently with antimalarial treatment or 28 d later. We hypothesized that delayed iron supplementation would be associated with greater incorporation and better hematologic recovery.
We enrolled 100 children aged 6-59 mo with malaria and hemoglobin concentrations of 50.0-99.9 g/L who presented to Mulago Hospital, Kampala, into a randomized trial of iron therapy. All children were administered antimalarial treatment. Children with zinc protoporphyrin (ZPP) ≥80 μmol/mol heme were randomly assigned to start iron supplementation concurrently with the antimalarial treatment [immediate iron (I) group] or 28 d later [delayed iron (D) group]. All children were administered iron-stable isotope (57)Fe on day 0 and (58)Fe on day 28. We compared the percentage of iron incorporation at the start of supplementation (I group at day 0 compared with D group at day 28, aim 1) and hematologic recovery at day 56 (aim 2).
The percentage of iron incorporation (mean ± SE) was greater at day 28 in the D group (16.5% ± 1.7%) than at day 0 in the I group (7.9% ± 0.5%; P < 0.001). On day 56, concentrations of hemoglobin and ZPP and plasma ferritin, soluble transferrin receptor (sTfR), hepcidin, and C-reactive protein did not differ between the groups. On day 28, the hemoglobin (mean ± SD) and plasma iron markers (geometric mean; 95% CI) reflected poorer iron status in the D group than in the I group at this intervening time as follows: hemoglobin (105 ± 15.9 compared with 112 ± 12.4 g/L; P = 0.04), ferritin (39.3 μg/L; 23.5, 65.7 μg/L compared with 79.9 μg/L; 58.3, 110 μg/L; P = 0.02), sTfR (8.9 mg/L; 7.4, 10.7 mg/L compared with 6.7 mg/L; 6.1, 7.5 mg/L; P = 0.01), and hepcidin (13.3 ng/mL; 8.3, 21.2 ng/mL compared with 38.8 ng/mL; 28.3, 53.3 ng/mL; P < 0.001).
Delaying the start of iron improves incorporation but leads to equivalent hematologic recovery at day 56 in Ugandan children with malaria and anemia. These results do not demonstrate a clear, short-term benefit of delaying iron. This trial was registered at clinicaltrials.gov as NCT01754701.
由于疟疾引发的炎症,在抗疟治疗同时开始的铁剂治疗可能吸收不佳。推迟开始铁剂治疗可能会使铁的吸收和分布更好。
我们比较了在抗疟治疗同时开始补充铁剂或28天后开始补充铁剂的儿童的红细胞铁掺入情况。我们假设延迟补充铁剂会使铁掺入量增加且血液学恢复更好。
我们将100名年龄在6至59个月、患有疟疾且血红蛋白浓度为50.0至99.9 g/L、前往坎帕拉穆拉戈医院就诊的儿童纳入一项铁剂治疗随机试验。所有儿童均接受抗疟治疗。锌原卟啉(ZPP)≥80 μmol/mol血红素的儿童被随机分配在抗疟治疗同时开始补充铁剂[即时铁(I)组]或28天后开始补充铁剂[延迟铁(D)组]。所有儿童在第0天接受铁稳定同位素(57)Fe,在第28天接受(58)Fe。我们比较了补充铁剂开始时的铁掺入百分比(I组第0天与D组第28天,目标1)以及第56天的血液学恢复情况(目标2)。
D组第28天的铁掺入百分比(均值±标准误)(16.5%±1.7%)高于I组第0天的(7.9%±0.5%;P<0.001)。在第56天,两组之间的血红蛋白、ZPP以及血浆铁蛋白、可溶性转铁蛋白受体(sTfR)、铁调素和C反应蛋白浓度无差异。在第28天,在此中间时间点,D组的血红蛋白(均值±标准差)和血浆铁标志物(几何均值;95%置信区间)反映出的铁状态比I组差,如下所示:血红蛋白(105±15.9与112±12.4 g/L;P = 0.04)、铁蛋白(39.3 μg/L;23.5,65.7 μg/L与79.9 μg/L;58.3,110 μg/L;P = 0.02)、sTfR(8.9 mg/L;7.4,10.7 mg/L与6.7 mg/L;6.1,7.5 mg/L;P = 0.01)和铁调素(13.3 ng/mL;8.3,21.2 ng/mL与38.8 ng/mL;28.3,53.3 ng/mL;P<0.001)。
在患有疟疾和贫血的乌干达儿童中,延迟开始补充铁剂可改善铁掺入,但在第56天导致同等的血液学恢复。这些结果未显示出延迟补充铁剂有明显的短期益处。该试验在clinicaltrials.gov上注册为NCT01754701。